SCHEMBL13941709

SCHEMBL13941709

C=C(N)N/N=C(\C)c1ccc2[nH]c(C(=O)Nc3ccc(N)cc3)cc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 3/20 0.49
▸ PIK3CA P42336 3/20 0.49
▸ NHERF1 O14745 2/20 0.47
▸ PLD2 O14939 1/20 0.47
▸ PLD1 Q13393 1/20 0.47
▸ TP53 P04637 2/20 0.47
▸ NPC1 O15118 5/20 0.46
▸ RAB9A P51151 4/20 0.46
▸ RXFP1 Q9HBX9 3/20 0.46
▸ POLB P06746 2/20 0.45
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ LMNA P02545 2/20 0.42
▸ PKM P14618 1/20 0.42
▸ APEX1 P27695 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ PYGL P06737 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13941584 0.94 EGFR (0.49) EGFRPIK3CANHERF1PLD2PLD1
SCHEMBL13941711 0.93 EGFR (0.50) EGFRPIK3CANHERF1PLD2PLD1
SCHEMBL13941634 0.91 EGFR (0.56) EGFRPIK3CANHERF1PLD2PLD1
SCHEMBL13941579 0.90 EGFR (0.47) EGFRPIK3CANHERF1PLD2PLD1
SCHEMBL13941533 0.90 EGFR (0.49) EGFRPIK3CANHERF1PLD2PLD1
SCHEMBL13941702 0.89 EGFR (0.48) EGFRPIK3CANHERF1PLD2PLD1
SCHEMBL13941706 0.88 MAOA (0.54) EGFRPIK3CANHERF1PLD2PLD1
SCHEMBL13941620 0.87 NHERF1 (0.63) EGFRPIK3CANHERF1TP53NPC1
SCHEMBL13941649 0.87 RXFP1 (0.55) EGFRPIK3CANHERF1PLD2PLD1
SCHEMBL13941632 0.86 NPC1 (0.55) EGFRPIK3CANHERF1PLD2PLD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765802-B2 Kinase inhibitors, compositions thereof, and methods of use therewith PROVID PHARMACEUTICALS, INC. (US) 2014-07-01 — — US disclosed
US-20090018141-A1 KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH PROVID PHARMACEUTICALS, INC. 2009-01-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018141-A1 KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH CHEK2, ATM, CHEK1 EGFR 1827/4885PIK3CA 821/4885NHERF1 4282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback